The main therapeutic options for iron deficiency anemia in pregnancy

an integrative revision

Abstract

Anemia is defined by a decrease in hemoglobin levels below reference values ​​in laboratory tests, with its main etiology being iron deficiency. An important risk factor for the development of anemia is pregnancy, which shows the importance of checking the most effective medications in pregnant women. Therefore, the present study sought to evaluate the efficacy, safety and tolerability of therapeutic options for the treatment of iron deficiency anemia in pregnant women. The integrative review used the following databases: MEDLINE, LILACS and Scielo. 14 randomized controlled clinical trials were selected. These articles brought evaluations of the following drugs: ferrous ascorbate, ferrous bis-glycinate, ferric carboxymaltose, ferric hydroxide-polymaltose complex, low molecular weight iron dextran, iron amino acid chelate, elemental iron, ferrous fumarate, lactoferrin, micronized dispersible ferric pyrophosphate with alpha-lactalbumin, intravenous iron sucrose, ferrous glycine sulfate and ferrous sulfate. Thus, it was observed that some drugs are effective, safe and with minimal adverse effects when compared to ferrous sulfate. Therefore, it is suggested that the Ministry of Health adopt new medications for the treatment of iron deficiency anemia in pregnant women.

Published
2025-06-04